<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081572</url>
  </required_header>
  <id_info>
    <org_study_id>5P30A1028697</org_study_id>
    <nct_id>NCT03081572</nct_id>
  </id_info>
  <brief_title>Platelet Function on Abacavir and Tenofovir</brief_title>
  <official_title>Differences in Platelet Function in Patients on Abacavir Versus Tenofovir Based Antiretroviral Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a small observational study aimed at observing differences in platelet function in&#xD;
      HIV patients on abacavir versus tenofovir based anti-HIV drugs. There is some correlation&#xD;
      between platelet activation and cardiovascular disease- this study will act as a pilot to see&#xD;
      if platelet activation among abacavir users may explain the correlation between abacavir and&#xD;
      cardiovascular disease in HIV positive patients.&#xD;
&#xD;
      This study will enroll 44 participants total; 22 on abacavir-based treatment, 22 on&#xD;
      tenofovir-based treatment. There is only one study visit which includes a blood draw,&#xD;
      physical assessment, and review of medical history.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Actual">February 15, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>At screening visit</time_frame>
    <description>Degree of platelet aggregation in response to adenosine diphosphate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Markers of coagulation</measure>
    <time_frame>At screening visit</time_frame>
    <description>sGPVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Markers of Coagulation</measure>
    <time_frame>At screening visit</time_frame>
    <description>sPSelectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of endothelial function</measure>
    <time_frame>At screening visit</time_frame>
    <description>sICAM</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Platelet Aggregation, Spontaneous</condition>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Abacavir Group</arm_group_label>
    <description>HIV positive individuals currently taking an abacavir based regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir Group</arm_group_label>
    <description>HIV positive individuals currently taking a tenofovir based regime</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Platelet aggregation</intervention_name>
    <description>Platelet aggregation</description>
    <arm_group_label>Abacavir Group</arm_group_label>
    <arm_group_label>Tenofovir Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive non smokers who are on a stable antiretroviral regimen containing either&#xD;
        abacavir or tenofovir&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Stable antiretroviral regimen for &gt; 3months containing either abacavir or tenofovir&#xD;
&#xD;
          -  Suppressed HIV viral load&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current cigarette smoking&#xD;
&#xD;
          -  Pre-existing platelet disorder&#xD;
&#xD;
          -  current or recent (last 6 months) antiplatelet therapy&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical AIDS Research and Education Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

